12 completed, 8 unknown, 4 recruiting, 3 terminated. 30 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 30 | Completed 12, Unknown 8, Recruiting 4, Terminated 3, Not yet recruiting 2, Withdrawn 1 |
Follow Paclitaxel: new trials by email Literature Review of Paclitaxel trials Research Report on Paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Trial of SFI Plus PD-1 Inhibitors and PBC in Resectable NSCLC (SFI-NSCLC) Shenqi Fuzheng Injection - Tear Disorder, Resectable Locally Advanced Non-Squamous NSCLC | Phase 4 | Not yet recruiting | Anhui Provincial Cancer Hospital | 30 | 2026-10-15 | 2026-10-29 |
| A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin, Paclitaxel - Neoplasms, Endometrial | Phase 4 | Not yet recruiting | GlaxoSmithKline | 100 | 2026-08-17 | 2026-06-17 |
| Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) Paclitaxel Oral Solution, PD-1/PD-L1 inhibitor (eg. Tislelizumab) - Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 4 | Recruiting | Anhui Provincial Cancer Hospital | 107 | 2026-07-24 | 2026-08-04 |
| Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT) - NSCLC (Non-small Cell Lung Cancer) | Phase 4 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 78 | 2026-06-25 | 2026-08-10 |
| Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics Bifidobacterium Bifidum Oral Capsule, Cisplatin, Carboplatin - Cancer Therapy-related Cardiovascular Toxicity | Phase 4 | Unknown | Peking University Third Hospital | 200 | 2023-02-15 | 2023-02-16 |
| Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy - NSCLC | Phase 4 | Terminated | Galvanize Therapeutics, Inc. | 5 | 2023-02-01 | 2024-07-19 |
| Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES) Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy - Esophageal Squamous Cell Carcinoma | Phase 4 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 32 | 2022-10-10 | 2023-06-29 |
| Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer Paclitaxel - Breast Cancer, Metastatic Gastric Cancer | Phase 4 | Recruiting | University of Michigan Rogel Cancer Center | 22 | 2022-03-28 | 2026-07-02 |
| Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer Eribulin Injection [Halaven], Paclitaxel injection - Breast Cancer Female, Neoplasm, Breast | Phase 4 | Unknown | Institut fuer Frauengesundheit | 82 | 2021-03-11 | 2023-04-18 |
| A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) Pembrolizumab, Carboplatin, Paclitaxel - Squamous Cell Carcinoma of Head and Neck | Phase 4 | Completed | Merck Sharp & Dohme LLC | 101 | 2020-10-27 | 2025-06-19 |
| A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer Abemaciclib, Fulvestrant, Standard Chemotherapy - Metastatic Breast Cancer | Phase 4 | Terminated | Eli Lilly and Company | 4 | 2019-08-14 | 2021-08-24 |
| Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer pegylated liposomal doxorubicin, paclitaxel, Carboplatin - Efficacy and Safety | Phase 4 | Unknown | Women's Hospital School Of Medicine Zhejiang University | 396 | 2019-03-19 | 2022-07-18 |
| A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) - Metastatic Breast Cancer | Phase 4 | Completed | GBG Forschungs GmbH | 130 | 2018-03-01 | 2024-10-01 |
| Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response Paclitaxel - Breast Neoplasm Female | Phase 4 | Recruiting | University of Wisconsin, Madison | 50 | 2017-03-13 | 2026-06-16 |
| Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Paclitaxel, Carboplatin, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 60 | 2017-01-01 | 2019-03-08 |
| Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) Dose dense AC-P, Dose dense AC, FEC-D - Breast Cancer | Phase 4 | Terminated | Ottawa Hospital Research Institute | 2 | 2016-08-30 | 2025-12-04 |
| Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen Carboplatin, Cyclophosphamide, Docetaxel - Breast Cancer | Phase 4 | Completed | Hoffmann-La Roche | 110 | 2015-08-18 | 2022-10-12 |
| Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Endostar, Changchun marina, cisplatin - Non-small Cell Lung Cancer | Phase 4 | Unknown | Nanjing NingQi Medicine Science and Technology Co., Ltd. | 400 | 2015-02-01 | 2015-08-04 |
| Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments Paclitaxel liposome injection, Paclitaxel injection - Solid Tumors | Phase 4 | Unknown | Nanjing Luye Sike Pharmaceutical Co., Ltd. | 36 | 2014-08-01 | 2014-08-27 |
| Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer Paclitaxel, Carboplatin, Paclitaxel, Epirubicin - Metastatic Breast Cancer | Phase 4 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 120 | 2013-12-01 | 2015-12-22 |
Showing 20 of 30. Sign in to see all of them.
Breast Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (3) · Coronary Artery Disease (2) · Carcinoma, Large Cell (1) · Carcinoma, Ovarian Epithelial (1) · Coronary Stenosis (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Lung Diseases (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Ovarian Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Hoffmann-La Roche (4) · Anhui Provincial Cancer Hospital (2) · Seung-Jung Park (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Eli Lilly and Company (1) · Eurocor GmbH (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · GBG Forschungs GmbH (1) · Galvanize Therapeutics, Inc. (1) · GlaxoSmithKline (1) · Institut fuer Frauengesundheit (1) · Merck Sharp & Dohme LLC (1) · Nanjing Luye Sike Pharmaceutical Co., Ltd. (1) · Nanjing NingQi Medicine Science and Technology Co., Ltd. (1) · National Cancer Institute, Naples (1)
China (10) · United States (5) · Germany (4) · Canada (2) · Italy (2) · South Korea (2) · Argentina (1) · Australia (1) · Bangladesh (1) · Brazil (1) · India (1) · Netherlands (1) · Puerto Rico (1) · Taiwan (1) · United Kingdom (1)
Seung-Jung Park, MD, PhD (2) · Anil Kukreja, MD (1) · Ciro Gallo, M.D. (1) · Daniel L Hertz, PharmD, PhD (1) · Francesco Perrone, M.D., Ph.D. (1) · Gennaro Daniele, M.D., Ph.D. (1) · Giuseppe Sangiorgi, MD (1) · Irene Floriani, Ph.D. (1) · Jin Li, Doctor (1) · John Hilton, Dr. (1) · Junke Fu (1)
PMID 17762336, PMID 20969765, PMID 26028407, PMID 26291008, PMID 27413711, PMID 28196905, PMID 28535181, PMID 30040817, PMID 30280641, PMID 31590988, PMID 32599071, PMID 33084020, PMID 33096027, PMID 33333328, PMID 33538338, PMID 33931498, PMID 34086039, PMID 34462317, PMID 34516829, PMID 35576956, PMID 36166026, PMID 37478883, PMID 37921708, PMID 38460751, PMID 38512301, PMID 38610980, PMID 39038265, PMID 39305910, PMID 39415516, PMID 39614293, PMID 41709925, PMID 41784638, PMID 42575837
2009 (1), 2016 (1), R01CA284747 (1)